SCHEMBL8926628

SCHEMBL8926628

C=CCC(Cc1ccc(Cl)c(Cl)c1)N(COCC)C(=O)c1cc(C)cc(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.36
TSHR P16473 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.34
KDM4E B2RXH2 2/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
MAOB P27338 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PNMT P11086 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
PSMB5 P28074 1/20 0.31
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8925596 0.90 EPHX2 (0.34) L3MBTL1KDM4EALDH1A1PSEN1PSEN2
SCHEMBL7622297 0.73 PPARA (0.37) KDM4EMAOBALDH1A1PSEN1PSEN2
SCHEMBL8483788 0.72 PSMB5 (0.37) KDM4EALDH1A1PSMB5LMNAMAPT
SCHEMBL8926136 0.70 TACR1 (0.47) TACR1SMN1; SMN2TSHRSLC6A2SLC6A4
SCHEMBL6005075 0.63 KMO (0.48) SLC6A2SLC6A4SLC6A3PNMTPSMB5
SCHEMBL6005266 0.63 KMO (0.48) SLC6A2SLC6A4SLC6A3PNMTPSMB5
SCHEMBL7492398 0.63 SLC6A3 (0.48) SMN1; SMN2TSHRSLC6A2SLC6A4SLC6A3
SCHEMBL8582269 0.62 PNMT (0.47) TACR1TSHRSLC6A2SLC6A4SLC6A3
SCHEMBL8581618 0.62 PNMT (0.47) TACR1TSHRSLC6A2SLC6A4SLC6A3
SCHEMBL2163757 0.62 SMN1; SMN2 (0.56) TACR1SMN1; SMN2TSHRL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5646144-A FOR TREATING DISORDERS IN WHICH SUBSTANCE P PLAYS A PART IN DEVELOPMENT CIBA-GEIGY CORPORATION (US) 1997-07-08 US disclosed
EP-0532456-B1 1-Acylpiperidine derivatives and their use as substance P antagonists CIBA GEIGY AG (CH) 1995-03-29 EP disclosed
US-5310743-A Substance P antagonist CIBA-GEIGY CORP. (US) 1994-05-10 US disclosed
EP-0532456-A1 1-Acylpiperidine derivatives and their use as substance P antagonists CIBA-GEIGY AG (CH) 1993-03-17 EP disclosed